Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 354 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies MOST POPULAR Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle July 20, 2021 2022 ASCO Annual Meeting: A New Targeted Therapy Combination for Low-Grade Brain... June 6, 2022 For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions June 3, 2021 Cancer Survivor Kicked Out Of Bridal Party Cause She Refused To... August 29, 2019 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... Study Adds to Debate about Screening for Melanoma
